NovaBay Regains Worldwide Rights to Its Aganocide Compounds From Alcon
16 juin 2011 07h00 HE
|
NovaBay Pharmaceuticals, Inc.
NovaBay and Alcon Terminate Collaboration Agreement
EMERYVILLE, Calif., June 16, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company...
NovaBay Pharmaceuticals to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc. on May 24
23 mai 2011 08h00 HE
|
NovaBay Pharmaceuticals, Inc.
Management to Webcast Presentation at 12:00 PM PDT / 3:00 PM EDT
EMERYVILLE, Calif., May 23, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE-AMEX:NBY) announces that Ron Najafi,...
NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis
18 mai 2011 06h00 HE
|
NovaBay Pharmaceuticals, Inc.
Encouraging and Unexpected Results Found in Patients Infected with Epidemic Keratoconjunctivitis (EKC) Viruses and All Patients with Blurred Vision
CONFERENCE CALL AND WEBCAST TO BE HELD AT...
NovaBay Pharmaceuticals to Announce Results of Phase 2 Clinical Trial for Treatment of Adenoviral Conjunctivitis
17 mai 2011 17h00 HE
|
NovaBay Pharmaceuticals, Inc.
Conference Call and Webcast Scheduled for Tomorrow, May 18 at 7:00 a.m. (PDT) / 10:00 a.m. (EDT)
EMERYVILLE, Calif., May 17, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE...
NovaBay Pharmaceuticals, Inc. Reports First Quarter Financial Results
16 mai 2011 19h40 HE
|
NovaBay Pharmaceuticals, Inc.
Company Strengthens Phase 2 Pipeline With the Initiation of a Phase 2b Trial for Urinary Catheter Blockage and Encrustation (UCBE)
Net Cash Flow Effectively Break-Even for Over Two Years While...
NovaBay Pharmaceuticals Spotlights Three New Aganocide(R) Compounds With Confirmed Activity Against Ophthalmic Pathogens
06 mai 2011 06h00 HE
|
NovaBay Pharmaceuticals, Inc.
Poster Presentation at the 2011 ARVO Conference Reviews NovaBay's Expanding
Portfolio of Aganocide Compounds Exhibiting Significant Activity against Viral,
Bacterial and Fungal Ocular...
NovaBay Pharmaceuticals Spotlights Positive Results From NeutroPhase(R) Study of 26 Patients With Chronic Non-Healing Wounds
19 avr. 2011 07h00 HE
|
NovaBay Pharmaceuticals, Inc.
Presentation at 2011 Symposium on Advanced Wound Care (SAWC)
Highlights the Efficacy of NovaBay's Novel Anti-Infective
EMERYVILLE, Calif., April 19, 2011 (GLOBE NEWSWIRE) -- NovaBay...
NovaBay Pharmaceuticals Awarded 1st Place for Outstanding Scientific Presentation at The Simon Foundation for Continence Conference
14 avr. 2011 08h00 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 14, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) has won the 1st Place Award for Outstanding Poster Presentation at the 2011 conference of The Simon...
NovaBay Pharmaceuticals Spotlights Positive Results for Its Novel Anti-Infective at 2011 Simon Foundation for Continence Conference
12 avr. 2011 07h00 HE
|
NovaBay Pharmaceuticals, Inc.
Presentation Highlights the Efficacy of the Lead Aganocide Compound as a Potential Break-Through Treatment for Prevention of Urinary Catheter Blockage and Encrustation (UCBE) Often Leading to...
NovaBay Pharmaceuticals Releases CEO Webcast on Business and Clinical Developments From Its Four Business Units
28 mars 2011 14h13 HE
|
NovaBay Pharmaceuticals, Inc.
Audio and Slide Presentation From the Recent Roth Capital Partners 23rd Annual Growth Stock Conference Now Available On-Line
EMERYVILLE, Calif., March 28, 2011 (GLOBE NEWSWIRE) -- NovaBay...